Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:AMGN News 30 December 2025 - 5 February 2026

Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen shares surged 8.2% to $366.20 Wednesday after quarterly earnings beat forecasts and the company issued a 2026 outlook above consensus. Investors focused on progress in Amgen’s MariTide obesity program, which could allow less frequent dosing. The company reported Q4 revenue of $9.9 billion and adjusted EPS of $5.29. Amgen plans $2.6 billion in 2026 capital spending and capped share buybacks at $3 billion.
5 February 2026
·····
Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus

Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus

Amgen shares jumped 8.5% to $367.52 in afternoon trading Tuesday, outpacing a broader market decline. The company reported Q4 revenue up 9% to $9.9 billion and projected 2026 sales as high as $38.4 billion. Investors focused on late-stage trials for obesity drug MariTide. The FDA has requested withdrawal of Tavneos, but Amgen is refusing.
4 February 2026
·····
Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen shares fell 0.3% to $341.88 Friday after disclosing plans to end its 2021 partnership with Kyowa Kirin, which will regain global rights to the eczema drug rocatinlimab. Amgen will report fourth-quarter and full-year earnings after markets close Feb. 3, with investors focused on pipeline priorities following the Kyowa Kirin exit.
31 January 2026
·····
Amgen stock price slips from record close as AMGN heads into earnings and the obesity-drug race

Amgen stock price slips from record close as AMGN heads into earnings and the obesity-drug race

Amgen shares closed Friday down 0.7% at $344.75, after nearly reaching record highs earlier in the week. About 3.8 million shares traded hands. Investors are awaiting Amgen’s Feb. 3 earnings and updates on its obesity drug candidate, MariTide. The company’s board declared a $2.52 per share Q1 dividend, payable March 6.
25 January 2026
····
Amgen stock pulled back after a six-day run — here’s what investors watch next week

Amgen stock pulled back after a six-day run — here’s what investors watch next week

Amgen shares fell 0.7% to $344.75 Friday, ending a six-day winning streak after reaching a 52-week high of $349.98 on Thursday. The stock remains up about 4% for the week. Investors are awaiting the Feb. 3 earnings call for updates on Amgen’s obesity drug pipeline and guidance. The board approved a $2.52 quarterly dividend, payable March 6 to shareholders of record by Feb. 13.
24 January 2026
····
Amgen stock on watch as JPMorgan conference speech looms after two-day slide

Amgen stock on watch as JPMorgan conference speech looms after two-day slide

New York, Jan 11, 2026, 16:51 EST — Market closed. Amgen (AMGN.O) shares head into Monday’s session with investors looking to Chief Executive Robert Bradway’s J.P. Morgan Healthcare Conference remarks for the next clear catalyst. (Amgen) The annual healthcare conference is one of the first big trade-and-talk events of the year for drugmakers. Traders will be listening for what management says — and what it does not say — about pipeline timing, deal appetite and any near-term pressure on pricing. Amgen closed at $326.10 on Friday, down 1.21%, after a 3.37% drop on Thursday, according to Investing.com data. The broader
11 January 2026
···
Amgen stock slides into weekend as JPMorgan healthcare conference looms

Amgen stock slides into weekend as JPMorgan healthcare conference looms

NEW YORK, Jan 10, 2026, 17:43 EST — Market closed. Shares of Amgen Inc. closed down on Friday, marking a second consecutive day of losses as investors prepared for a new batch of healthcare conference updates. The timing is key as deal discussions pick up again with executives and bankers gathering in San Francisco for the J.P. Morgan Healthcare Conference, a major early-year event for the sector. Jeremy Meilman, JPMorgan’s global co-head of healthcare investment banking, noted that firms are “dusting off the playbook on the art of the possible.” (Reuters) Amgen finds itself in a familiar yet tricky position:
10 January 2026
·····
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

NEW YORK, January 7, 2026, 19:17 EST — After-hours Amgen shares (AMGN.O) rose 3.5% to $341.64 in Wednesday’s regular session and were last near that level after the bell. UBS assumed coverage with a buy rating and a $380 price target, saying it sees “upside from EPS and pipeline.” Why this matters now is simple: investors are testing whether Amgen’s next growth bets can outrun erosion in older blockbusters. The FDA on Tuesday approved Amneal’s denosumab biosimilars — near-copies of complex biologic drugs that typically enter at lower prices — as alternatives to Amgen’s Prolia and Xgeva, products with about
8 January 2026
······
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

New York, Jan 5, 2026, 21:27 EST — Market closed AbbVie Inc shares closed down 4% on Monday at $220.18, lagging a Wall Street rally that pushed the Dow to a record high. The move mattered because drug and biotech names were among the day’s laggards as investors rotated into energy and financials after Venezuela headlines lifted oil-linked stocks. The NYSE Arca Pharmaceutical Index fell about 1.4% and the SPDR S&P Biotech ETF slid 1.1%, while the Health Care Select Sector SPDR ETF dipped 0.3%. Yahoo Finance AbbVie also put a near-term spotlight on its calendar, saying it will present
6 January 2026
·······
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

NEW YORK, December 30, 2025, 2:56 PM ET — Regular session Amgen Inc. shares were down 0.4% at $328.32 at 2:56 p.m. ET on Tuesday, after trading between $325.90 and $330.18. The modest move matters because investors are grading Amgen’s pipeline for new growth while several mature products face price pressure and biosimilar competition. Oncology and obesity remain two key swing factors for the stock heading into 2026. Biotech stocks lagged, with the iShares Nasdaq Biotechnology ETF down about 1.1%, while the healthcare sector ETF was roughly flat and the S&P 500 ETF hovered near unchanged. Verastem Oncology said it
30 December 2025
·····
Amgen stock slips to $330 as year-end pullback hits Wall Street; Fed minutes and MariTide updates in focus

Amgen stock slips to $330 as year-end pullback hits Wall Street; Fed minutes and MariTide updates in focus

NEW YORK, December 29, 2025, 22:14 ET — Market closed Amgen shares fell 1% on Monday, ending the session down $3.30 at $329.63. StockAnalysis The decline matters now because traders are heading into the final sessions of the year with U.S. indexes near record territory and liquidity thinner than usual. That backdrop can amplify moves in large-cap healthcare stocks even without a company-specific trigger. Reuters Wall Street’s main indexes closed lower, led by a retreat in heavyweight technology names, Reuters reported. “It’ll turn out to be a buying opportunity,” said Hank Smith, director and head of investment strategy at Haverford
30 December 2025
·····
1 2

Stock Market Today

Reckitt share price ends week near a one-year high as RKT investors eye special dividend and March results

Reckitt share price ends week near a one-year high as RKT investors eye special dividend and March results

7 February 2026
London, Feb 7, 2026, 08:16 GMT — Market closed. Reckitt Benckiser Group (RKT.L) shares ended Friday at 6,400 pence, down 0.2%, after touching a one-year high of 6,432 pence. About 2.6 million shares changed hands. (London South East) The stock is now trading through the tail-end of a chunky one-off cash return. Reckitt has set a 235 pence-a-share special dividend for Feb. 20 and is pairing it with a 24-for-25 share consolidation to keep the quoted share price and per-share metrics broadly comparable after the payout. (Investegate) In the wider market, Britain’s FTSE 100 finished Friday up 0.6%, with gains
GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
BAT share price closes near 52-week high as buyback rolls on ahead of results week

BAT share price closes near 52-week high as buyback rolls on ahead of results week

7 February 2026
British American Tobacco shares closed up 1.2% at 4,609 pence Friday, near a 52-week high. The company disclosed further share buybacks and management share purchases ahead of its Feb. 12 full-year results. BAT bought 121,668 shares for cancellation on Feb. 5. Investors await updates on nicotine alternatives and cash returns.
Go toTop